The COVID-19 pandemic, and the need to accelerate development and distribution of vaccines, has required companies and governments to take on considerable risk in the hope that vaccines now under development prove to be safe and effective.
Vaccines developed during other pandemics have shown what can go wrong with traditional supply agreements. In response to COVID-19, governments around the world are taking varying approaches for entering into such agreements with vaccine manufacturers. Only time will show which approach proves the best. However, as Eva Marchese and Abhishek Kumar suggest in PharmTech, risk-sharing contracts will offer the best opportunity for balancing risks and benefits for developers, governments, and patients.